Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

Journal of Neurology

Volumn 261, Issue 6, 2014, Pages 1203-1209

  Kasai, Takashi ^a   Tokuda, Takahiko ^a   Ishii, Ryotaro ^a   Ishigami, Noriko ^a   Tsuboi, Yoshio ^b   Nakagawa, Masanori ^a   Mizuno, Toshiki ^a   El Agnaf, Omar M A ^c  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Biomarker; Cerebrospinal fluid; Creutzfeldt Jakob disease; ELISA; Tau; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; TAU PROTEIN; PROTEIN 14 3 3;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; CASE CONTROL STUDY; CEREBROSPINAL FLUID; MIDDLE AGED; VERY ELDERLY;

14-3-3 PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CASE-CONTROL STUDIES; CREUTZFELDT-JAKOB SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; ROC CURVE; TAU PROTEINS;

EID: 84903638867     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7334-7     Document Type: Article

References (16)

1. Satoh K, Shirabe S, Tsujino A, Eguchi H, Motomura M, Honda H, Tomita I, Satoh A, Tsujihata M, Matsuo H, Nakagawa M, Eguchi K (2007) Total tau protein in cerebrospinal fluid and diffusion-weighted MRI as an early diagnostic marker for Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 24:207-212
2. Hamlin C, Puoti G, Berri S, Sting E, Harris C, Cohen M, Spear C, Bizzi A, Debanne SM, Rowland DY (2012) A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology 79:547-552. doi: 10.1212/WNL.0b013e318263565f
3. Goedert M, Crowther RA, Garner CC (1991) Molecular characterization of microtubule-associated proteins tau and MAP2. Trends Neurosci 14:193-199
4. Fournier JG (2008) Cellular prion protein electron microscopy: attempts/limits and clues to a synaptic trait. Implications in neurodegeneration process. Cell Tissue Res 332:1-11. doi: 10.1007/s00441-007-0565-5
5. Clinton J, Forsyth C, Royston MC, Roberts GW (1993) Synaptic degeneration is the primary neuropathological feature in prion disease: a preliminary study. Neuroreport 4:65-68
6. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, Ingham C, Sayers AR, Brown DA, Fraser JR (2000) Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol 26:41-54
7. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OM (2006) Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349:162-166
8. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J (2010) DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133:713-726. doi: 10.1093/brain/awq008
9. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG (2008) Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213:315-325. doi: 10.1016/j.expneurol.2008.06.004
10. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10:230-240. doi: 10.1016/S1474-4422(11)70014-X
11. Beyer K (2007) Mechanistic aspects of Parkinson's disease: α-synuclein and the biomembrane. Cell Biochem Biophys 47:285-299
12. Zeidler M, Gibbs CJ Jr, Meslin F (1998) WHO mannual for strengthening diagnosis and surveillance of Creuzfeldt-Jakob disease. World Health Organization, Geneva, pp 47-51
13. Nishimura T, Takeda M, Nakamura Y, Yosbida Y, Arai H, Sasaki H, Shouji M, Hirai S, Khise K, Tanaka K, Hamamoto M, Yamamoto H, Matsubayashi T, Urakami K, Adachi Y, Nakashima K, Toji H, Nakamura S, Yoshida H (1998) Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find Exp Clin Pharmacol 20:227-235
14. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J, Allsop D (2003) α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17:1945-1947
15. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R et al (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38:643-648
16. Foulds PG, Yokota O, Thurston A, Davidson Y, Ahmed Z, Holton J, Thompson JC, Akiyama H, Arai T, Hasegawa M, Gerhard A, Allsop D, Mann DM (2012) Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol Dis 45:188-195. doi: 10.1016/j.nbd.2011.08.003